Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 17;11(11):1458–1471. doi: 10.1002/psp4.12855

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Regeneron Pharmaceuticals, Inc. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

External posterior predictive check of cemiplimab exposure for patients with R/M CC from EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 using the final PopPK model. Gray open circles represent individually observed concentrations. The red solid and dashed lines represent the observed median and the 5th and 95th percentiles, respectively. The shaded areas represent the 90% CIs for the median, 5th, and 95th percentiles of the simulated data. CI, confidence interval; ENGOT, European Network of Gynecological Oncological Trial; GOG, Gynecologic Oncology Group; PopPK, population pharmacokinetic; R/M CC, recurrent or metastatic cervical cancer.